All participants will initially undergo a run-in period on standardised medium-dose ICS/LABA to confirm persistent lack of ...

Children with asthma experienced fewer exacerbations and better control with dupilumab regardless of the duration of their ...

Dupilumab and omalizumab are both effective adjuvant treatments for adults with bullous pemphigoid, though dupilumab may provide better outcomes.

The likelihood for avoidance of five clinically important outcomes in patients with COPD and type 2 inflammation was greater with dupilumab vs. placebo, according to findings from a win ratio analysis ...

The poster presentations will be available on Connect’s website under the Presentations and Publications section.

A new study published in the Journal of the European Academy of Dermatology and Venerology found dupilumab to have a ...

Sanofi and Regeneron's Dupixent (dupilumab) has gained approval from the FDA for chronic spontaneous urticaria (CSU) ...

Pregnant patients with T2IDs using dupilumab did not have an increased rate of adverse events when compared with patients not receiving dupilumab.

In a clinical report published online May 19 in Pediatrics, the American Academy of Pediatrics presents updated guidance for ...

Sanjay Ramakrishnan, MD, senior lecturer, University of Western Australia, discusses the value of the win ratio approach in evaluating treatment effects in chronic obstructive pulmonary disease (COPD) ...

Real-world data from Australian patients show that upadacitinib demonstrates strong efficacy in treating atopic dermatitis, ...